- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022–2025 · career development · K01
The Role of Mitochondrial TNAP in Adaptive Thermogenesis
Yizhi Sun · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R50
Molecular origins and evolution to treatment resistance in genitourinary cancers
Jihye Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Development of A Mindfulness-Based Mobile Health Intervention for Patients Coping with Pain from Advanced Malignancies
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R00
Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders
Evanna Louisa Mills · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Translation initiation as a therapeutic target in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cyclin C-CDK8/19 kinases in development and in cancer
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Andrew Hantel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022 · grant · Formation de recherche pour les médecins résidents - Formation de spécialité en recherche
Formation de recherche pour les médecins résidents - Formation de spécialité en recherche — Immunothérapie, Cancer du poumon
Andréanne Gagné · Dana-Farber Cancer Institute · funded by Fonds de Recherche du Québec - Santé
2022–2027 · research · R37
Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · career development · K00
Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage
Camila Robles-Oteiza · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Genomic Diversity of Prostate Cancer Across the African Diaspora
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · award
Oncogenic roles for non-canonical proteins in medulloblastoma
John Prensner · Dana-Farber Cancer Institute · funded by American Cancer Society
2022–2027 · research · R01
Synthetic lethalities to cell cycle disruption in glioma
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Molecular prediction of myeloma in African Americans
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · career development · K01
The Role of Mitochondrial TNAP in Adaptive Thermogenesis
Yizhi Sun · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2023 · career development · K99
Modeling and Dissecting Epigenetic Drivers of Gliomagenesis
Gilbert J Rahme · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
Geoffrey I Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R00
SESORRS endoscopy for the staging and evaluation of colorectal cancer
Fay Nicolson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · award
Cellular Barcoding to Define Melanoma Drug Resistance and Cell of Origin
E. Elizabeth Patton · Dana-Farber Cancer Institute · funded by Melanoma Research Alliance
2022–2025 · fellowship · F32
Elucidating novel molecular mechanisms of irisin-mediated effects via integrin
Mu A · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2023 · career development · K08
Deciphering non-canonical translation in high risk medulloblastoma
John Prensner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R37
Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Altered metabolism and machine learning for pancreatic cancer early detection
Michael H. Rosenthal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Mechanisms and Therapy of Chronic Graft-vs.-Host Disease
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer
William A Freed-Pastor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation
Erin M Parry · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Development of A Mindfulness-Based Mobile Health Intervention for Patients Coping with Pain from Advanced Malignancies
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2023 · career development · K99
SESORRS endoscopy for the staging and evaluation of colorectal cancer
Fay Nicolson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · research · R21
Defining the impact of mutational drivers on the immune microenvironment of CLL
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · RCRP
Targeting MYB in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Andrew Lane · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R01
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PCRP
Interrogating Metastatic Prostate Cancer Biological and Clinical Trajectories Through Integrative Data Science
Eliezer Van Allen · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R01
Selective disruption of histone deacetylase complexes using protein interaction modulators
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
